Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease.
Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, McGill JB, McMurray JJ, Parfrey PS, Parving HH, Pereira BJ, Remuzzi G, Singh AK, Solomon SD, Stehman-Breen C, Toto RD, Pfeffer MA.
Mix TC, et al. Among authors: de zeeuw d.
Am Heart J. 2005 Mar;149(3):408-13. doi: 10.1016/j.ahj.2004.09.047.
Am Heart J. 2005.
PMID: 15864229